Al­tim­mune to put its in­cretin in­to ad­dic­tion tri­als; Tar­sus aims to raise $125M

Plus, news about Hei­del­berg, Ac­cropeu­tics, Al­lar­i­ty Ther­a­peu­tics, Ca­dren­al and In­ovio:

Al­tim­mune to test its in­cretin in ad­dic­tion: Fol­low­ing the path set by No­vo Nordisk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER